<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="publisher-id">MD</journal-id>
      <journal-title-group>
        <journal-title>Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0025-7974</issn>
      <issn pub-type="epub">1536-5964</issn>
      <publisher>
        <publisher-name>Wolters Kluwer Health</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24378738</article-id>
      <article-id pub-id-type="pmc">4616329</article-id>
      <article-id pub-id-type="publisher-id">MD001318</article-id>
      <article-id pub-id-type="doi">10.1097/MD.0000000000000011</article-id>
      <article-id pub-id-type="art-access-id">00001</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Study</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Inflammatory Arthritis in Patients With Myelodysplastic Syndromes</article-title>
        <subtitle>A Multicenter Retrospective Study and Literature Review of 68 Cases</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Mekinian</surname>
            <given-names>Ars&#xE8;ne</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Braun</surname>
            <given-names>Thorsten</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Decaux</surname>
            <given-names>Olivier</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Falgarone</surname>
            <given-names>G&#xE9;raldine</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Toussirot</surname>
            <given-names>Eric</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Raffray</surname>
            <given-names>Loic</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Omouri</surname>
            <given-names>Mohamed</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gombert</surname>
            <given-names>Bruno</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Wazieres</surname>
            <given-names>Benoit</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Buchdaul</surname>
            <given-names>Anne-Laure</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ziza</surname>
            <given-names>Jean-Marc</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Launay</surname>
            <given-names>David</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Denis</surname>
            <given-names>Guillaume</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Madaule</surname>
            <given-names>Serge</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rose</surname>
            <given-names>Christian</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grignano</surname>
            <given-names>Eric</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fenaux</surname>
            <given-names>Pierre</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fain</surname>
            <given-names>Olivier</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <on-behalf-of>on behalf of the Club Rhumatismes et Inflammation (CRI), Groupe Francophone des My&#xE9;lodysplasies (GFM), and Soci&#xE9;t&#xE9; Nationale Fran&#xE7;aise de M&#xE9;decine Interne (SNFMI)</on-behalf-of>
      </contrib-group>
      <aff>From the Service de m&#xE9;decine interne (AM, EG, OF), Universit&#xE9; Paris 13, AP-HP, H&#xF4;pital Jean Verdier, Bondy; Service d&#x2019;h&#xE9;matologie clinique (TB, PF), Universit&#xE9; Paris 13, AP-HP, Avicenne, Bobigny; Service de m&#xE9;decine interne (OD), Universit&#xE9; Rennes 1, H&#xF4;pital Universitaire de Rennes, Rennes; Service de rhumatologie (GF), Universit&#xE9; Sorbonne Paris Cit&#xE9;, Universit&#xE9; Paris 13, Li2P, EA4222, H&#xF4;pital Avicenne, Bobigny; Centre Investigation Clinique Bioth&#xE9;rapie CBT-506 &amp; Service de rhumatologie (ET), CHU Besan&#xE7;on, Besan&#xE7;on; Service de m&#xE9;decine interne (LR), CHU de Bordeaux, Bordeaux; Service de rhumatologie (MO), CH Romilly/Seine; Service de m&#xE9;decine interne (BG), H&#xF4;pital de La Rochelle, La Rochelle; Service de m&#xE9;decine interne et g&#xE9;riatrique (BDW), CHU N&#xEE;mes, N&#xEE;mes; Service de m&#xE9;decine interne (A-LB), CH Douai, Douai; Service de rhumatologie (J-MZ), CH Croix Saint Simon, Paris; Service de m&#xE9;decine interne (DL), CHU Lille, Universit&#xE9; Lille II, Lille; Service de m&#xE9;decine interne (GD), H&#xF4;pital de Rochefort, Rochefort; Service de m&#xE9;decine interne (SM), CHG Albi, Albi; and Service d&#x2019;h&#xE9;matologie clinique (CR), H&#xF4;pital Saint-Vincent de Paul, UC Lille, Univ Nord de France, Lille; France.</aff>
      <author-notes>
        <corresp>Reprints: Ars&#xE8;ne Mekinian, MD, Service de M&#xE9;decine Interne, Universit&#xE9; Paris 13, AP-HP, H&#xF4;pital Jean Verdier, 93140 Bondy, France (e-mail: <email>arsene.mekinian@jvr.aphp.fr</email>).</corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>02</day>
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <volume>93</volume>
      <issue>1</issue>
      <elocation-id>1-10</elocation-id>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 by Lippincott Williams &amp; Wilkins</copyright-statement>
        <copyright-year>2014</copyright-year>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="medi-93-01.pdf"/>
      <abstract abstract-type="toc">
        <p>Supplemental Digital Content is available in the text.</p>
      </abstract>
      <abstract>
        <title>Abstract</title>
        <p>We describe the characteristics and outcome of inflammatory arthritis in patients with myelodysplastic syndrome (MDS) in a French multicenter retrospective study.</p>
        <p>Twenty-two patients with MDS (median age, 77.5 yr [interquartile range, 69&#x2013;81]; 10 women) were included. Inflammatory arthritis presented as polyarthritis in 17 cases (77%) and with symmetric involvement in 15 cases (68%). At diagnosis, the median disease activity score 28 based on C-reactive protein (DAS28-CRP) was 4.5 [2&#x2013;6.5]. Two patients had anti-citrullinated protein antibodies (ACPAs), and 1 had radiologic erosions. The median time between the diagnoses of arthritis and MDS was 10 months [6&#x2013;42], with a median articular symptom duration of 3 months [2&#x2013;8]. The diagnosis of both diseases was concomitant in 6 cases (27%); arthritis preceded MDS in 12 cases (55%), and occurred after MDS in 4 (18%). While the number of swollen and tender joints significantly decreased during follow-up, as did the median DAS28-CRP (from 4.3 [3.8&#x2013;4.6] at baseline to 2.9 [1.75&#x2013;3.3]; p &lt; 0.05), CRP remained elevated (CRP &gt;20 mg/L) in 8 patients (42%). Nevertheless, radiographic progression and new ACPA positivity were not observed during a median follow-up of 29 months [9&#x2013;76]. While most of the patients were treated with steroids (n = 16) for arthritis, additional treatment was administered in only 4 patients (hydroxychloroquine, n = 2; sulfasalazine [Salazopyrin] and etanercept, n = 1, respectively). Eleven patients died during follow-up from acute myeloid leukemia (n = 5); infections (n = 3); or cerebral bleeding, cardiorespiratory failure, or undetermined cause (n = 1, respectively).</p>
        <p>Inflammatory arthritis associated with MDS can have various presentations and is often seronegative and nonerosive. Steroids alone are the most common treatment in MDS-associated arthritis, but that treatment is insufficient to control arthritis. Steroid-sparing strategies need to be identified.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>SDC</meta-name>
          <meta-value>T</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="introduction">
      <title>INTRODUCTION</title>
      <p>Myelodysplastic syndromes (MDSs) are clonal marrow stem cell disorders characterized by ineffective hematopoiesis resulting in cytopenia and a high risk of progression to acute myeloid leukemia (AML). MDSs are frequently associated with various autoimmune and systemic features, but the mechanisms of this association remain insufficiently understood.<xref rid="R19" ref-type="bibr">19</xref> The association with inflammatory arthritis, including rheumatoid or undifferentiated arthritis, polymyalgia rheumatica, and remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome, has primarily been described in case reports and small series.<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R34" ref-type="bibr">34</xref> Information is still lacking regarding the evolution of the disorders as well as the use of and response to specific treatments for MDS-associated arthritis.</p>
      <p>In this French multicenter, retrospective study, we described the characteristics of MDS-associated inflammatory arthritis as well as the outcome and specific treatments. A literature review of MDS-associated arthritis was also performed.</p>
    </sec>
    <sec sec-type="materials-methods">
      <title>PATIENTS AND METHODS</title>
      <sec sec-type="subjects">
        <title>Patient Selection</title>
        <p>Data were collected retrospectively from the physicians in charge of the patients. The physicians were asked to complete a standardized questionnaire distributed online with the support of the Club Rhumatismes et Inflammation (available online at <ext-link ext-link-type="uri" xlink:href="http://www.cri-net.com">http://www.cri-net.com</ext-link>) and the National Society of Internal Medicine (SNFMI) (see Supplemental Digital Content, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/MD/A25,">http://links.lww.com/MD/A25,</ext-link> English version of the questionnaire). The inclusion criteria were as follows: 1) MDS according to the 2008 World Health Organization (WHO) criteria;<xref rid="R47" ref-type="bibr">47</xref> 2) &gt;2 tender joints and/or swollen joints for &gt;6 weeks, with a diagnosis of inflammatory arthritis; 3) absence of extraarticular systemic features; 4) time between arthritis and MDS diagnosis &lt;5 years. The exclusion criteria included crystal and septic arthritis. The study was performed in accordance with the ethical standards of the Helsinki Declaration.</p>
      </sec>
      <sec>
        <title>Data Collection</title>
        <p>One physician (AM) used the predefined standardized form to collect patient data. Patient clinical, laboratory, and radiologic data as well as treatments were recorded at baseline, at different points during the follow-up, and at the last visit (Table <xref ref-type="table" rid="T1">1</xref>). The evaluated joints included the metacarpophalangeal (&#xD7;10) and proximal interphalangeal (&#xD7;10) joints, wrists (&#xD7;2), metatarsophalangeal joint (&#xD7;10), shoulders (&#xD7;2), knees (&#xD7;2), ankles and elbows (&#xD7;4). Laboratory data included standard tests, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum fibrinogen, serum gammaglobulins, CH50, C3, C4, rheumatoid factor, anti-citrullinated protein antibodies (ACPAs), and antinuclear antibodies (ANAs) if available.</p>
        <table-wrap id="T1" position="float">
          <label>TABLE 1</label>
          <caption>
            <p>Baseline Characteristics and Follow-Up of Patients in the French Study</p>
          </caption>
          <graphic xlink:href="medi-93-01-g001"/>
        </table-wrap>
      </sec>
      <sec>
        <title>Definitions</title>
        <p>The 1987 and 2010 American College of Rheumatology (ACR) criteria for rheumatoid arthritis were retrospectively applied to all patients.<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R4" ref-type="bibr">4</xref> The response to treatment of arthritis was assessed using a subjective physician assessment and according to the DAS28-CRP variation (except for patients with polymyalgia rheumatica). Steroid dependence was defined as a daily prednisone dose &#x2265;20 mg.</p>
        <p>MDS was classified according to the 2008 WHO criteria.<xref rid="R47" ref-type="bibr">47</xref> The International Prognostic Scoring System (IPSS) was retrospectively assessed, including the extent of cytopenia, cytogenetics, and the percentage of blasts in the bone marrow.<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R23" ref-type="bibr">23</xref> The response of MDS to treatment was retrospectively defined according to the 2006 International Working Group criteria.<xref rid="R14" ref-type="bibr">14</xref></p>
      </sec>
      <sec>
        <title>Statistical Analysis</title>
        <p>Descriptive statistics included the medians (interquartile ranges [IQRs]) as appropriate for continuous variables and frequencies (percentages) for categorical variables. To consider missing data in the analyses, the results were expressed comparatively to the total number of available data. The Fisher exact test was used to compare categorical variables, and the nonparametric Mann-Whitney test or Wilcoxon test was used to compare continuous variables. A p value &lt; 0.05 was considered significant. Statistical analyses were performed using Prism software (GraphPad Software, San Diego, CA).</p>
      </sec>
      <sec>
        <title>Literature Review</title>
        <sec>
          <title>Search Strategy</title>
          <p>A literature search was performed by 2 investigators (AM and OF) using MEDLINE (National Library of Medicine, Bethesda, MD) (searching records from January 1987 to October 2012) using the following keywords: myelodysplastic syndrome, arthritis, rheumatoid arthritis, undifferentiated arthritis, systemic diseases, auto-immune diseases, polymyalgia rheumatica, and RS3PE. All articles with sufficient data were included in the literature review. The literature search yielded 31 citations; 23 were analyzed and included in the present study (7 were excluded because of insufficient data concerning arthritis, and 1 paper was in Japanese).<xref rid="R6" ref-type="bibr">6</xref>&#x2013;<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R15" ref-type="bibr">15</xref>&#x2013;<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R19" ref-type="bibr">19</xref>&#x2013;<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R24" ref-type="bibr">24</xref>&#x2013;<xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R34" ref-type="bibr">34</xref>&#x2013;<xref rid="R43" ref-type="bibr">43</xref>,<xref rid="R46" ref-type="bibr">46</xref> Among these 31 studies, only 5 included more than 3 patients, with the largest study including 6 described cases (see Tables <xref ref-type="table" rid="T2">2</xref>&#x2013;<xref ref-type="table" rid="T4">4</xref>).</p>
          <table-wrap id="T2" position="float">
            <label>TABLE 2</label>
            <caption>
              <p>Rheumatoid Arthritis and Undifferentiated Arthritis Associated With MDS, Previous Reports</p>
            </caption>
            <graphic xlink:href="medi-93-01-g002"/>
          </table-wrap>
          <table-wrap id="T3" position="float">
            <label>TABLE 3</label>
            <caption>
              <p>Polymyalgia Rheumatica Associated With MDS, Present and Previous Reports</p>
            </caption>
            <graphic xlink:href="medi-93-01-g003"/>
          </table-wrap>
          <table-wrap id="T4" position="float">
            <label>TABLE 4</label>
            <caption>
              <p>RS3PE Associated With MDS, Present and Previous Reports</p>
            </caption>
            <graphic xlink:href="medi-93-01-g004"/>
          </table-wrap>
        </sec>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>RESULTS</title>
      <sec sec-type="subjects">
        <title>Baseline Patient Characteristics</title>
        <p>Twenty-two patients with MDS and arthritis (median age, 77.5 yr [IQR, 69&#x2013;81]; 12 men, 10 women) were included. The diagnosis of MDS included refractory cytopenia with unilineage dysplasia (RCUD) (n = 1), refractory anemia with ring sideroblasts (RARS) (n = 1), refractory anemia with excess blasts-1 (RAEB1) (n = 5), refractory anemia with excess blasts-2 (RAEB2) (n = 3), refractory cytopenia with multilineage dysplasia (RCMD)(n = 8), MDS with 5q deletion (n = 2), chronic myelomonocytic leukemia (CMML) (n = 1), and unclassified (MDS-U) (n = 1).) Cytogenetics were available in 15 patients and were favorable in 11 cases including normal karyotype in 5/15 cases (33%), intermediate and poor in 2 cases each. The IPSS was low (n = 3), intermediate-1 (n = 7), and intermediate-2 (n = 5). The median medullar blast count was 4.5 [0&#x2013;15], with a normal karyotype in 5/15 cases (33%).</p>
        <p>Inflammatory arthritis presented as polyarthritis in 17 cases (77%) and with symmetric involvement in 15 cases (68%). Four patients had isolated shoulder arthralgia, compatible with polymyalgia rheumatica, and 4 (18%) had bilateral pitting edema of the hands with polyarthritis consistent with RS3PE syndrome. At diagnosis, rheumatoid factor was present in 5 patients (23%), and 2 of the 5 had ACPAs (9%), with radiologic erosions in 1 case. The median numbers of ACR-1987 and ACR-2010 rheumatoid arthritis criteria present were 3 [2.5&#x2013;4] and 5 [4&#x2013;7], respectively, with 8/18 patients (44%) and 6/18 (33%) fulfilling the rheumatoid arthritis criteria, respectively. The 2 sets of rheumatoid arthritis criteria were significantly correlated, with a kappa of 0.6 (p &lt; 0.05).</p>
        <p>The median time between the diagnoses of arthritis and MDS was 10 months [6&#x2013;42], with an articular symptom duration of 3 months [2&#x2013;8]. The appearance of these 2 diseases was concomitant in 6 cases (27%); arthritis preceded MDS in 12 cases (55%) and occurred after MDS in 4 (18%).</p>
      </sec>
      <sec>
        <title>Outcome</title>
        <p>The treatments administered during the follow-up and evolution of arthritis and MDS are shown in Table <xref ref-type="table" rid="T1">1</xref>. While the number of swollen and tender joints and the median DAS28-CRP significantly decreased during follow-up (from 4.3 [3.8&#x2013;4.6] at baseline to 2.9 [1.75&#x2013;3.3]; p &lt; 0.05), CRP remained elevated (CRP &gt;20 mg/L in 8 [42%] vs. 14 patients at baseline). Nevertheless, no patients showed any radiographic progression or new ACPA positivity during a follow-up period of 29 months [9&#x2013;76]. No significant correlation was found between MDS evolution and inflammatory arthritis, although among patients with stable MDS or responders to MDS treatment, 10 patients (77%) experienced arthritis remission compared to 4 (50%) in patients with progressive disease (Figure <xref ref-type="fig" rid="F1">1</xref>) (p = 0.2). The arthritis treatments included steroids in 16/22 patients; only 4 patients received other treatments (hydroxychloroquine, n = 2; sulfasalazine [Salazopyrin] and etanercept, n = 1, respectively). For MDS, 6 patients received potentially disease-modifying drugs, including azacitidine in 4 cases and lenalidomide in 2, while other treatments included androgens (n = 1), cyclosporine (n = 1), and erythropoietin (n = 8) for cytopenias. Among 4 patients receiving azacitidine, articular symptoms improved in 2 patients, with 1 patient achieving hematologic improvement and 1 patient stable while on azacitidine. No patient receiving lenalidomide improved in respect to articular symptoms. Complications that could be related to MDS and/or steroids were noted in 11 cases: infections (n = 4), osteoporosis and fractures (n = 2), steroid-related myopathy (n = 2), cardiovascular failure (n = 2), and secondary hemochromatosis (n = 3). Eleven patients (50%) died during follow-up as a result of AML (n = 5), infections (n = 3), cerebral bleeding, cardiorespiratory failure or undetermined cause (n = 1, respectively).</p>
        <fig id="F1" position="float">
          <label>FIGURE 1</label>
          <caption>
            <p>Inflammatory arthritis outcome in relation to MDS evolution (data available for 21 of 22 patients).</p>
          </caption>
          <graphic xlink:href="medi-93-01-g005"/>
        </fig>
      </sec>
      <sec>
        <title>Literature Review</title>
        <sec>
          <title>Rheumatoid Arthritis or Undifferentiated Arthritis</title>
          <p>For the literature review we analyzed 42 cases with rheumatoid or undifferentiated arthritis, including 14 cases from the current study (Table <xref ref-type="table" rid="T2">2</xref>). Arthritis was typically polyarticular (n = 34; 83%) and symmetrical (80%) with rheumatoid factor in 12/40 cases (30%), and radiologic erosions were present in only 2 cases (5%). The median time between the diagnosis of arthritis and MDS was 9 months [3.5&#x2013;24]; arthritis preceded MDS in 21 cases (50%), and the 2 diseases were concomitant in 5 cases (12%). The number of ACR-1987 rheumatoid arthritis criteria met was 4 [2.5&#x2013;4], and &#x2265;4 were met in 21/41 patients (51%). Corticosteroids were used in 29/41 cases (71%), with daily prednisone at 30 mg [15&#x2013;35]. Another disease-modifying antirheumatic drug was used in only 8 cases: hydroxychloroquine (n = 5) and etanercept, tacrolimus, and sulfasalazine (Salazopyrin) (n = 1, respectively). The types of MDS were RCUD (n = 4), RAEB-1/-2 (n = 15), RARS (n = 3), MDS with 5q deletion (n = 4), CMML (n = 6), and RCMD (n = 8). With a median follow-up of 12 months [8&#x2013;33], 15/28 (54%) of the MDS patients had received treatment, including low-dose cytarabine, (n = 3), azacitidine (n = 2), androgens (n = 2), VP16 (n = 1), cyclosporine (n = 1), and erythropoietin (n = 5). MDS progression occurred in 10/23 cases (43%), with death in 11/19 cases (58%), whereas uncontrolled arthritis persisted in 17/34 cases (50%), with steroid dependence in 25%.</p>
        </sec>
        <sec>
          <title>Polymyalgia Rheumatica</title>
          <p>Eighteen cases of polymyalgia rheumatica, including our 4 cases, were analyzed (Table <xref ref-type="table" rid="T3">3</xref>). Giant cell arteritis was reported in 3 cases (17%). The median time between the diagnosis of polymyalgia rheumatica and MDS was 4 months [3&#x2013;27]; arthritis preceded MDS in 10 cases (56%), and the 2 diseases were concomitant in 3 cases (17%). Prednisone was used in all cases, with a median daily dose of 20 mg [19&#x2013;40]. Additional treatment was administered in 3 cases (methotrexate in 2 cases and hydroxychloroquine in 1 case). Specific MDS treatment was administered in 6/16 cases: erythropoietin (n = 4) and azacitidine, lenalidomide, and androgens (n = 1, respectively). MDS progression occurred in 5/17 cases. Over a median follow-up of 29 months [10&#x2013;47], polymyalgia rheumatica was in remission in 7/18 cases (39%), and 8/18 cases (44%) had steroid dependence.</p>
        </sec>
        <sec>
          <title>RS3PE Syndrome</title>
          <p>Eight cases of RS3PE, including our 4 cases, were analyzed (Table <xref ref-type="table" rid="T4">4</xref>). No patient presented with rheumatoid factor or radiologic erosion. Corticosteroids were used in all patients, with a daily dose of 14 mg [10&#x2013;20], and additional hydroxychloroquine treatment in 1 case. MDS was treated in 5/7 cases: erythropoietin (n = 2) and androgens, azacitidine, and lenalidomide (n = 1, respectively). MDS progression was observed in 1/5 cases. Over a median follow-up of 22 months [11&#x2013;30], arthritis remission was achieved in 4/7 cases (57%), and steroid dependence was reported in 2/7 cases (29%).</p>
        </sec>
        <sec sec-type="subjects">
          <title>All Patients With MDS Arthritis</title>
          <p>Among 68 patients with MDS-associated arthritis, the median follow-up was 20 months [8&#x2013;36]. The median time between the diagnosis of arthritis and MDS was 5 months [1&#x2013;24]; arthritis preceded MDS in 34 cases (50%), and the 2 diseases were concomitant in 9 cases (13%) (Figure <xref ref-type="fig" rid="F2">2</xref>). Additionally, 12/49 (24%) patients were positive for rheumatoid factor, and 3/51 (6%) exhibited radiologic erosions. MDS-associated arthritis fulfilled the ACR-1987 rheumatoid arthritis criteria in 21 cases (31%), presented as polymyalgia rheumatica in 18 cases (26%), RS3PE syndrome in 8 cases (12%), and undifferentiated arthritis in 21 cases (31%). As shown in Table <xref ref-type="table" rid="T5">5</xref>, MDS and arthritis appeared less than 12 months apart in most patients with RS3PE, polymyalgia rheumatica, and undifferentiated arthritis, and in 57% of patients with RA. Steroids were used in 54 cases (78%) with a median daily dose of 20 mg <xref rid="R15" ref-type="bibr">15</xref>&#x2013;<xref rid="R35" ref-type="bibr">35</xref> of prednisone. Complete arthritis remission was achieved in 22/65 cases (34%). The majority of patients had RAEB-1/&#x2212;2 (n = 23/66; 35%). MDS was treated in 24/40 cases (60%), with stable disease in 26/57 cases (46%) and disease progression in 16/44 cases (36%).</p>
          <fig id="F2" position="float">
            <label>FIGURE 2</label>
            <caption>
              <p>Time between arthritis and MDS diagnoses in all patients.</p>
            </caption>
            <graphic xlink:href="medi-93-01-g006"/>
          </fig>
          <table-wrap id="T5" position="float">
            <label>TABLE 5</label>
            <caption>
              <p>Delay Between Arthritis and MDS</p>
            </caption>
            <graphic xlink:href="medi-93-01-g007"/>
          </table-wrap>
        </sec>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>In the current study focusing on MDS-associated arthritis, we describe 4 rheumatologic patterns of MDS-associated arthritis: rheumatoid and undifferentiated arthritis, polymyalgia rheumatica, and RS3PE syndrome. Despite the frequent and persistent increase of acute-phase reactants, radiologic erosions appeared to be rare, in contrast to isolated rheumatoid arthritis. Specific rheumatoid arthritis treatments for MDS-associated arthritis and steroid-sparing agents were rarely used. MDS-associated arthritis appears to be more frequent in RAEB, and uncontrolled arthritis may evolve in parallel with the underlying MDS.</p>
      <p>The current study confirms and expands on the previous case reports and series of MDS-associated arthritis.<xref rid="R6" ref-type="bibr">6</xref>&#x2013;<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R15" ref-type="bibr">15</xref>&#x2013;<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R19" ref-type="bibr">19</xref>&#x2013;<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R24" ref-type="bibr">24</xref>&#x2013;<xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R34" ref-type="bibr">34</xref>&#x2013;<xref rid="R43" ref-type="bibr">43</xref>,<xref rid="R46" ref-type="bibr">46</xref> In particular, no specific rheumatologic features suggested MDS-associated arthritis, and despite polyarticular symmetrical arthritis and frequent inflammatory syndrome, the presence of rheumatoid factor was relatively rare. The presence of rheumatoid arthritis was frequent, but MDS-associated arthritis also appeared as polymyalgia rheumatica or RS3PE syndrome and remained undifferentiated arthritis in 32% of cases. The concomitant appearance of these features in less than 12 months in most of the patients highlights the link between these 2 diseases. A fortuitous association may have been present in particular for rheumatoid arthritis cases with more than 4 years&#x2019; delay. Radiologic destruction appears to be exceptional. Uncontrolled arthritis and steroid dependence were observed in as many as 50% and 30% of patients, respectively.</p>
      <p>MDS-associated arthritis frequently precedes MDS, and the possibility of inflammatory anemia could lead to the misdiagnosis of associated MDS. The persistence of anemia despite the remission of arthritis, associated cytopenia, and the importance of the increase of acute-phase reactants could indicate MDS. In patients with polymyalgia rheumatica, as described in the current study and the literature review, a poor response to steroids or steroid dependence should suggest the presence of associated MDS, particularly if cytopenia is observed.</p>
      <p>The presence of systemic manifestations did not appear to affect the MDS prognosis, except in patients with vasculitis and cryoglobulinemia.<xref rid="R16" ref-type="bibr">16</xref> The prognosis of MDS-associated arthritis may be less severe than the prognosis of MDS-associated vasculitis. However, similar to MDS vasculitis, MDS-associated arthritis is better controlled when the treatment of MDS is efficient.<xref rid="R18" ref-type="bibr">18</xref> Compared to non-MDS rheumatoid arthritis, the use of disease-modifying antirheumatic drugs and steroid-sparing agents is very rare and could most likely explain the poor response and high steroid dependence (20%&#x2013;40%). Nevertheless, the importance of steroid complications in patients with underlying hematologic immunodeficiency, as noted in our study, highlights the significance of steroid-sparing strategies.</p>
      <p>The mechanisms of autoimmune disorders associated with MDS remain poorly understood. The presence of immune dysregulation in MDS, as characterized by an impaired CD8 response and an imbalance of T-regulatory cells and Th-17 cells could also explain the emergence of autoimmune disorders.<xref rid="R1" ref-type="bibr">1</xref> Cytokine targeting, particularly TNF&#x3B1; antagonists, is alone insufficient for MDS treatment, but some reports have sparked interest for their use in MDS-associated autoimmune disorders.<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R45" ref-type="bibr">45</xref> Recently, hypomethylating agents, such as azacitidine and decitabine, have been shown to treat MDS effectively, and several reports have shown the benefits of these agents in MDS-associated autoimmune disorders.<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R44" ref-type="bibr">44</xref> Similarly, lenalidomide has been shown to have immunomodulatory action in malignancy and to induce an increase in T-regulatory cells and a Th-17 cell imbalance; it may also be effective for the treatment of autoimmune features.<xref rid="R33" ref-type="bibr">33</xref> In the current study, arthritis appeared to be better controlled in patients with stable MDS or treatment response. Nevertheless, large studies lack information on the impact of such treatments on MDS-associated autoimmune disorders, which is required to determine the optimal strategy in this setting.</p>
      <p>Some limitations should be mentioned, including the retrospective design, the amount of missing data, and the small number of patients in the current study. The impact of MDS treatment on arthritis activity was difficult to assess, as treatments have changed over the years, and in particular, the impact of hypomethylating agents on arthritis could not be evaluated due to the small number of patients treated. Additionally, the efficacy of other immunosuppressive and steroid-sparing agents could not be assessed because the number of patients with nonsteroid medications was low.</p>
      <sec sec-type="conclusion">
        <title>Conclusion</title>
        <p>Inflammatory arthritis associated with MDS has various presentations, but joint destruction and serologic features are relatively rare. Steroids remain the main treatment regimen in these patients, and disease-modifying antirheumatic drugs are rarely used, most likely due to the associated cytopenia and concern about their impact on disease progression. Better treatment strategies for MDS-associated arthritis remain to be identified in the era of the new MDS agents.</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="presented-at">
        <p>Presented at the 2012 American College of Rheumatology Congress, Washington, DC.</p>
        <p>The authors have no funding or conflicts of interest to disclose.</p>
      </fn>
      <fn fn-type="other">
        <p>Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal&#x2019;s Web site (<ext-link ext-link-type="uri" xlink:href="www.md-journal.com">www.md-journal.com</ext-link>).</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Aggarwal</surname><given-names>S</given-names></name><name><surname>van de Loosdrecht</surname><given-names>AA</given-names></name><name><surname>Alhan</surname><given-names>C</given-names></name><name><surname>Ossenkoppele</surname><given-names>GJ</given-names></name><name><surname>Westers</surname><given-names>TM</given-names></name><name><surname>Bontkes</surname><given-names>HJ</given-names></name></person-group>
<article-title>Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy</article-title>. <source><italic>Br J Haematol</italic></source>. <year>2011</year>;<volume>153</volume>:<fpage>568</fpage>&#x2013;<lpage>581</lpage>.<pub-id pub-id-type="pmid">21488861</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Aletaha</surname><given-names>D</given-names></name><name><surname>Neogi</surname><given-names>T</given-names></name><name><surname>Silman</surname><given-names>AJ</given-names></name><name><surname>Funovits</surname><given-names>J</given-names></name><name><surname>Felson</surname><given-names>DT</given-names></name><name><surname>Bingham</surname><given-names>CO</given-names><suffix>III</suffix></name><name><surname>Birnbaum</surname><given-names>NS</given-names></name><name><surname>Burmester</surname><given-names>GR</given-names></name><name><surname>Bykerk</surname><given-names>VP</given-names></name><name><surname>Cohen</surname><given-names>MD</given-names></name><name><surname>Combe</surname><given-names>B</given-names></name><name><surname>Costenbader</surname><given-names>KH</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Ferraccioli</surname><given-names>G</given-names></name><name><surname>Hazes</surname><given-names>JM</given-names></name><name><surname>Hobbs</surname><given-names>K</given-names></name><name><surname>Huizinga</surname><given-names>TW</given-names></name><name><surname>Kavanaugh</surname><given-names>A</given-names></name><name><surname>Kay</surname><given-names>J</given-names></name><name><surname>Kvien</surname><given-names>TK</given-names></name><name><surname>Laing</surname><given-names>T</given-names></name><name><surname>Mease</surname><given-names>P</given-names></name><name><surname>Menard</surname><given-names>HA</given-names></name><name><surname>Moreland</surname><given-names>LW</given-names></name><name><surname>Naden</surname><given-names>RL</given-names></name><name><surname>Pincus</surname><given-names>T</given-names></name><name><surname>Smolen</surname><given-names>JS</given-names></name><name><surname>Stanislawska-Biernat</surname><given-names>E</given-names></name><name><surname>Symmons</surname><given-names>D</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Upchurch</surname><given-names>KS</given-names></name><name><surname>Vencovsk</surname><given-names>J</given-names></name><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Hawker</surname><given-names>G</given-names></name></person-group>
<article-title>2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative</article-title>. <source><italic>Arthritis Rheum</italic></source>. <year>2010</year>;<volume>62</volume>:<fpage>2569</fpage>&#x2013;<lpage>2581</lpage>.<pub-id pub-id-type="pmid">20872595</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Al Ustwani</surname><given-names>O</given-names></name><name><surname>Francis</surname><given-names>J</given-names></name><name><surname>Wallace</surname><given-names>PK</given-names></name><name><surname>Ambrus</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Wetzler</surname><given-names>M</given-names></name></person-group>
<article-title>Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells</article-title>. <source><italic>Leuk Res</italic></source>. <year>2011</year>;<volume>35</volume>:<fpage>e35</fpage>&#x2013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">21247634</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Edworthy</surname><given-names>SM</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>McShane</surname><given-names>DJ</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>Cooper</surname><given-names>NS</given-names></name><name><surname>Healey</surname><given-names>LA</given-names></name><name><surname>Kaplan</surname><given-names>SR</given-names></name><name><surname>Liang</surname><given-names>MH</given-names></name><name><surname>Luthra</surname><given-names>HS</given-names></name><name><surname>Medsger</surname><given-names>TA</given-names></name><name><surname>Mitchell</surname><given-names>DM</given-names></name><name><surname>Neustadt</surname><given-names>DH</given-names></name><name><surname>Pinals</surname><given-names>RS</given-names></name><name><surname>Schaller</surname><given-names>JG</given-names></name><name><surname>Sharp</surname><given-names>JT</given-names></name><name><surname>Wilder</surname><given-names>RL</given-names></name><name><surname>Hunder</surname><given-names>GG</given-names></name></person-group>
<article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title>. <source><italic>Arthritis Rheum</italic></source>. <year>1988</year>;<volume>31</volume>:<fpage>315</fpage>&#x2013;<lpage>324</lpage>.<pub-id pub-id-type="pmid">3358796</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Baron</surname><given-names>F</given-names></name><name><surname>Suciu</surname><given-names>S</given-names></name><name><surname>Amadori</surname><given-names>S</given-names></name><name><surname>Muus</surname><given-names>P</given-names></name><name><surname>Zwierzina</surname><given-names>H</given-names></name><name><surname>Denzlinger</surname><given-names>C</given-names></name><name><surname>Delforge</surname><given-names>M</given-names></name><name><surname>Thyss</surname><given-names>A</given-names></name><name><surname>Selleslag</surname><given-names>D</given-names></name><name><surname>Indrak</surname><given-names>K</given-names></name><name><surname>Ossenkoppele</surname><given-names>G</given-names></name><name><surname>de Witte</surname><given-names>T</given-names></name></person-group>
<article-title>Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group</article-title>. <source><italic>Haematologica</italic></source>. <year>2012</year>;<volume>97</volume>:<fpage>529</fpage>&#x2013;<lpage>533</lpage>.<pub-id pub-id-type="pmid">22102701</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Berthelot</surname><given-names>JM</given-names></name><name><surname>Hamidou</surname><given-names>M</given-names></name><name><surname>Dauty</surname><given-names>M</given-names></name><name><surname>Rodet</surname><given-names>D</given-names></name><name><surname>Maugars</surname><given-names>Y</given-names></name><name><surname>Prost</surname><given-names>A</given-names></name></person-group>
<article-title>Joint manifestations in myelodysplastic syndromes. A report of three cases presenting as polymyalgia rheumatica</article-title>. <source><italic>Rev Rhum Engl Ed</italic></source>. <year>1997</year>;<volume>64</volume>:<fpage>95</fpage>&#x2013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">9085443</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Berthier</surname><given-names>S</given-names></name><name><surname>Magy</surname><given-names>N</given-names></name><name><surname>Gil</surname><given-names>H</given-names></name><name><surname>Schneider</surname><given-names>MB</given-names></name><name><surname>Vuitton</surname><given-names>DA</given-names></name><name><surname>Dupond</surname><given-names>JL</given-names></name></person-group>
<article-title>[Myelodysplasias and systemic diseases. A non-fortuitous association]</article-title>. <source><italic>Rev Med Interne</italic></source>. <year>2001</year>;<volume>22</volume>:<fpage>428</fpage>&#x2013;<lpage>432</lpage>.<pub-id pub-id-type="pmid">11402513</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Beyne-Rauzy</surname><given-names>O</given-names></name><name><surname>Revel</surname><given-names>V</given-names></name><name><surname>Desfossez</surname><given-names>V</given-names></name><name><surname>Bousquet</surname><given-names>E</given-names></name><name><surname>Nourhashemi</surname><given-names>F</given-names></name><name><surname>Adoue</surname><given-names>D</given-names></name></person-group>
<article-title>[RS3PE syndrome: an acute edematous polyarthritis of the elderly with variable prognosis]</article-title>. <source><italic>Ann Med Interne (Paris)</italic></source>. <year>2001</year>;<volume>152</volume>:<fpage>276</fpage>&#x2013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">11474377</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Billstrom</surname><given-names>R</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>Johansson</surname><given-names>B</given-names></name><name><surname>Mitelman</surname><given-names>F</given-names></name></person-group>
<article-title>Immune-mediated complications in patients with myelodysplastic syndromes&#x2014;clinical and cytogenetic features</article-title>. <source><italic>Eur J Haematol</italic></source>. <year>1995</year>;<volume>55</volume>:<fpage>42</fpage>&#x2013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">7615049</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Bouali</surname><given-names>F</given-names></name><name><surname>Berrah</surname><given-names>A</given-names></name><name><surname>Si Ahmed-Bouali</surname><given-names>D</given-names></name><name><surname>Harrieche</surname><given-names>F</given-names></name><name><surname>Benhalima</surname><given-names>M</given-names></name><name><surname>Hamladji</surname><given-names>RM</given-names></name><name><surname>Arrada</surname><given-names>M</given-names></name></person-group>
<article-title>[Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients)]</article-title>. <source><italic>Rev Med Interne</italic></source>. <year>2005</year>;<volume>26</volume>:<fpage>777</fpage>&#x2013;<lpage>783</lpage>.<pub-id pub-id-type="pmid">16203055</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Carvajal Mendez</surname><given-names>I</given-names></name><name><surname>Garcia Vadillo</surname><given-names>JA</given-names></name><name><surname>Herranz Varela</surname><given-names>A</given-names></name><name><surname>Gonzalez Alvaro</surname><given-names>I</given-names></name><name><surname>Casado Montero</surname><given-names>F</given-names></name><name><surname>Castaneda Sanz</surname><given-names>S</given-names></name></person-group>
<article-title>[Polyarthritis associated with myelodysplastic syndromes]</article-title>. <source><italic>Rev Clin Esp</italic></source>. <year>1996</year>;<volume>196</volume>:<fpage>539</fpage>&#x2013;<lpage>541</lpage>.<pub-id pub-id-type="pmid">8984541</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Castro</surname><given-names>M</given-names></name><name><surname>Conn</surname><given-names>DL</given-names></name><name><surname>Su</surname><given-names>WP</given-names></name><name><surname>Garton</surname><given-names>JP</given-names></name></person-group>
<article-title>Rheumatic manifestations in myelodysplastic syndromes</article-title>. <source><italic>J Rheumatol</italic></source>. <year>1991</year>;<volume>18</volume>:<fpage>721</fpage>&#x2013;<lpage>727</lpage>.<pub-id pub-id-type="pmid">1865418</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Chandran</surname><given-names>G</given-names></name><name><surname>Ahern</surname><given-names>MJ</given-names></name><name><surname>Seshadri</surname><given-names>P</given-names></name><name><surname>Coghlan</surname><given-names>D</given-names></name></person-group>
<article-title>Rheumatic manifestations of the myelodysplastic syndromes: a comparative study</article-title>. <source><italic>Aust N Z J Med</italic></source>. <year>1996</year>;<volume>26</volume>:<fpage>683</fpage>&#x2013;<lpage>688</lpage>.<pub-id pub-id-type="pmid">8958365</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Cheson</surname><given-names>BD</given-names></name><name><surname>Greenberg</surname><given-names>PL</given-names></name><name><surname>Bennett</surname><given-names>JM</given-names></name><name><surname>Lowenberg</surname><given-names>B</given-names></name><name><surname>Wijermans</surname><given-names>PW</given-names></name><name><surname>Nimer</surname><given-names>SD</given-names></name><name><surname>Pinto</surname><given-names>A</given-names></name><name><surname>Beran</surname><given-names>M</given-names></name><name><surname>de Witte</surname><given-names>TM</given-names></name><name><surname>Stone</surname><given-names>RM</given-names></name><name><surname>Mittelman</surname><given-names>M</given-names></name><name><surname>Sanz</surname><given-names>GF</given-names></name><name><surname>Gore</surname><given-names>SD</given-names></name><name><surname>Schiffer</surname><given-names>CA</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name></person-group>
<article-title>Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia</article-title>. <source><italic>Blood</italic></source>. <year>2006</year>;<volume>108</volume>:<fpage>419</fpage>&#x2013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">16609072</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Cuende</surname><given-names>E</given-names></name><name><surname>Guinea</surname><given-names>J</given-names></name><name><surname>Ortiz de Urbina</surname><given-names>F</given-names></name><name><surname>Torrabadella</surname><given-names>S</given-names></name><name><surname>Templado</surname><given-names>JA</given-names></name><name><surname>Vesga</surname><given-names>JC</given-names></name></person-group>
<article-title>Seronegative oligoarthritis in the course of refractory anaemia with excess blasts</article-title>. <source><italic>Rheumatology (Oxford)</italic></source>. <year>1999</year>;<volume>38</volume>:<fpage>373</fpage>&#x2013;<lpage>375</lpage>.<pub-id pub-id-type="pmid">10378719</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>de Hollanda</surname><given-names>A</given-names></name><name><surname>Beucher</surname><given-names>A</given-names></name><name><surname>Henrion</surname><given-names>D</given-names></name><name><surname>Ghali</surname><given-names>A</given-names></name><name><surname>Lavigne</surname><given-names>C</given-names></name><name><surname>Levesque</surname><given-names>H</given-names></name><name><surname>Hamidou</surname><given-names>M</given-names></name><name><surname>Subra</surname><given-names>JF</given-names></name><name><surname>Ifrah</surname><given-names>N</given-names></name><name><surname>Belizna</surname><given-names>C</given-names></name></person-group>
<article-title>Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study</article-title>. <source><italic>Arthritis Care Res (Hoboken)</italic></source>. <year>2011</year>;<volume>63</volume>:<fpage>1188</fpage>&#x2013;<lpage>1194</lpage>.<pub-id pub-id-type="pmid">21584947</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Enright</surname><given-names>H</given-names></name><name><surname>Jacob</surname><given-names>HS</given-names></name><name><surname>Vercellotti</surname><given-names>G</given-names></name><name><surname>Howe</surname><given-names>R</given-names></name><name><surname>Belzer</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>W</given-names></name></person-group>
<article-title>Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy</article-title>. <source><italic>Br J Haematol</italic></source>. <year>1995</year>;<volume>91</volume>:<fpage>403</fpage>&#x2013;<lpage>408</lpage>.<pub-id pub-id-type="pmid">8547082</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Fain</surname><given-names>O</given-names></name><name><surname>Hamidou</surname><given-names>M</given-names></name><name><surname>Cacoub</surname><given-names>P</given-names></name><name><surname>Godeau</surname><given-names>B</given-names></name><name><surname>Wechsler</surname><given-names>B</given-names></name><name><surname>Paries</surname><given-names>J</given-names></name><name><surname>Stirnemann</surname><given-names>J</given-names></name><name><surname>Morin</surname><given-names>AS</given-names></name><name><surname>Gatfosse</surname><given-names>M</given-names></name><name><surname>Hanslik</surname><given-names>T</given-names></name><name><surname>Belmatoug</surname><given-names>N</given-names></name><name><surname>Bletry</surname><given-names>O</given-names></name><name><surname>Cevallos</surname><given-names>R</given-names></name><name><surname>Delevaux</surname><given-names>I</given-names></name><name><surname>Fisher</surname><given-names>E</given-names></name><name><surname>Hayem</surname><given-names>G</given-names></name><name><surname>Kaplan</surname><given-names>G</given-names></name><name><surname>Le Hello</surname><given-names>C</given-names></name><name><surname>Mouthon</surname><given-names>L</given-names></name><name><surname>Larroche</surname><given-names>C</given-names></name><name><surname>Lemaire</surname><given-names>V</given-names></name><name><surname>Piette</surname><given-names>AM</given-names></name><name><surname>Piette</surname><given-names>JC</given-names></name><name><surname>Ponge</surname><given-names>T</given-names></name><name><surname>Puechal</surname><given-names>X</given-names></name><name><surname>Rossert</surname><given-names>J</given-names></name><name><surname>Sarrot-Reynauld</surname><given-names>F</given-names></name><name><surname>Sicard</surname><given-names>D</given-names></name><name><surname>Ziza</surname><given-names>JM</given-names></name><name><surname>Kahn</surname><given-names>MF</given-names></name><name><surname>Guillevin</surname><given-names>L</given-names></name></person-group>
<article-title>Vasculitides associated with malignancies: analysis of sixty patients</article-title>. <source><italic>Arthritis Rheum</italic></source>. <year>2007</year>;<volume>57</volume>:<fpage>1473</fpage>&#x2013;<lpage>1480</lpage>.<pub-id pub-id-type="pmid">18050165</pub-id></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Fain</surname><given-names>O</given-names></name><name><surname>Braun</surname><given-names>T</given-names></name><name><surname>Stirnemann</surname><given-names>J</given-names></name><name><surname>Fenaux</surname><given-names>P</given-names></name></person-group>
<article-title>Systemic and autoimmune manifestations in myelodysplastic syndromes</article-title>. <source><italic>Rev Med Interne</italic></source>. <year>2011</year>;<volume>32</volume>:<fpage>552</fpage>&#x2013;<lpage>559</lpage>.<pub-id pub-id-type="pmid">20850913</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>George</surname><given-names>SW</given-names></name><name><surname>Newman</surname><given-names>ED</given-names></name></person-group>
<article-title>Seronegative inflammatory arthritis in the myelodysplastic syndromes</article-title>. <source><italic>Semin Arthritis Rheum</italic></source>. <year>1992</year>;<volume>21</volume>:<fpage>345</fpage>&#x2013;<lpage>354</lpage>.<pub-id pub-id-type="pmid">1626280</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Giagounidis</surname><given-names>AA</given-names></name><name><surname>Haase</surname><given-names>S</given-names></name><name><surname>Germing</surname><given-names>U</given-names></name><name><surname>Heinsch</surname><given-names>M</given-names></name><name><surname>Aul</surname><given-names>C</given-names></name></person-group>
<article-title>Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion</article-title>. <source><italic>Acta Haematol</italic></source>. <year>2005</year>;<volume>113</volume>:<fpage>146</fpage>&#x2013;<lpage>149</lpage>.<pub-id pub-id-type="pmid">15802895</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Giannouli</surname><given-names>S</given-names></name><name><surname>Voulgarelis</surname><given-names>M</given-names></name><name><surname>Zintzaras</surname><given-names>E</given-names></name><name><surname>Tzioufas</surname><given-names>AG</given-names></name><name><surname>Moutsopoulos</surname><given-names>HM</given-names></name></person-group>
<article-title>Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study</article-title>. <source><italic>Rheumatology</italic></source>. <year>2004</year>;<volume>43</volume>:<fpage>626</fpage>&#x2013;<lpage>632</lpage>.<pub-id pub-id-type="pmid">14983106</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Greenberg</surname><given-names>P</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>LeBeau</surname><given-names>MM</given-names></name><name><surname>Fenaux</surname><given-names>P</given-names></name><name><surname>Morel</surname><given-names>P</given-names></name><name><surname>Sanz</surname><given-names>G</given-names></name><name><surname>Sanz</surname><given-names>M</given-names></name><name><surname>Vallespi</surname><given-names>T</given-names></name><name><surname>Hamblin</surname><given-names>T</given-names></name><name><surname>Oscier</surname><given-names>D</given-names></name><name><surname>Ohyashiki</surname><given-names>K</given-names></name><name><surname>Toyama</surname><given-names>K</given-names></name><name><surname>Aul</surname><given-names>C</given-names></name><name><surname>Mufti</surname><given-names>G</given-names></name><name><surname>Bennett</surname><given-names>J</given-names></name></person-group>
<article-title>International scoring system for evaluating prognosis in myelodysplastic syndromes</article-title>. <source><italic>Blood</italic></source>. <year>1997</year>;<volume>89</volume>:<fpage>2079</fpage>&#x2013;<lpage>2088</lpage>.<pub-id pub-id-type="pmid">9058730</pub-id></mixed-citation>
      </ref>
      <ref id="R24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Hamidou</surname><given-names>MA</given-names></name><name><surname>Derenne</surname><given-names>S</given-names></name><name><surname>Audrain</surname><given-names>MA</given-names></name><name><surname>Berthelot</surname><given-names>JM</given-names></name><name><surname>Boumalassa</surname><given-names>A</given-names></name><name><surname>Grolleau</surname><given-names>JY</given-names></name></person-group>
<article-title>Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study</article-title>. <source><italic>Rheumatology</italic></source>. <year>2000</year>;<volume>39</volume>:<fpage>417</fpage>&#x2013;<lpage>420</lpage>.<pub-id pub-id-type="pmid">10817775</pub-id></mixed-citation>
      </ref>
      <ref id="R25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Hebbar</surname><given-names>M</given-names></name><name><surname>Hebbar-Savean</surname><given-names>K</given-names></name><name><surname>Fenaux</surname><given-names>P</given-names></name></person-group>
<article-title>[Systemic diseases in myelodysplastic syndromes]</article-title>. <source><italic>Rev Med Interne</italic></source>. <year>1995</year>;<volume>16</volume>:<fpage>897</fpage>&#x2013;<lpage>904</lpage>.<pub-id pub-id-type="pmid">8570952</pub-id></mixed-citation>
      </ref>
      <ref id="R26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Hernandez-Beriain</surname><given-names>JA</given-names></name><name><surname>Cuesta-Callardo</surname><given-names>I</given-names></name><name><surname>Segura-Garcia</surname><given-names>C</given-names></name></person-group>
<article-title>Remitting seronegative symmetrical synovitis with pitting edema: a rheumatic manifestation of myelodysplastic syndrome?</article-title>
<source><italic>Rev Rhum Engl Ed</italic></source>. <year>1996</year>;<volume>63</volume>:<fpage>629</fpage>&#x2013;<lpage>330</lpage>.<pub-id pub-id-type="pmid">8938875</pub-id></mixed-citation>
      </ref>
      <ref id="R27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Hubscher</surname><given-names>O</given-names></name><name><surname>Vilches</surname><given-names>A</given-names></name><name><surname>Solmesky</surname><given-names>S</given-names></name><name><surname>Riveros</surname><given-names>D</given-names></name></person-group>
<article-title>Polymyalgia rheumatica in patients with myelodysplastic syndromes</article-title>. <source><italic>J Rheumatol</italic></source>. <year>1996</year>;<volume>23</volume>:<fpage>792</fpage>&#x2013;<lpage>793</lpage>.<pub-id pub-id-type="pmid">8730155</pub-id></mixed-citation>
      </ref>
      <ref id="R28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Kalra</surname><given-names>L</given-names></name><name><surname>Delamere</surname><given-names>JP</given-names></name></person-group>
<article-title>Lymphoreticular malignancy and monoclonal gammopathy presenting as polymyalgia rheumatica</article-title>. <source><italic>Br J Rheumatol</italic></source>. <year>1987</year>;<volume>26</volume>:<fpage>458</fpage>&#x2013;<lpage>459</lpage>.<pub-id pub-id-type="pmid">3480012</pub-id></mixed-citation>
      </ref>
      <ref id="R29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Kaufman</surname><given-names>LD</given-names></name><name><surname>Bahou</surname><given-names>WF</given-names></name><name><surname>Fromowitz</surname><given-names>FB</given-names></name></person-group>
<article-title>Myelodysplasia presenting as monoarthritis</article-title>. <source><italic>J Rheumatol</italic></source>. <year>1997</year>;<volume>24</volume>:<fpage>1446</fpage>&#x2013;<lpage>1447</lpage>.<pub-id pub-id-type="pmid">9228155</pub-id></mixed-citation>
      </ref>
      <ref id="R30">
        <label>30.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Kohli</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>RM</given-names></name></person-group>
<article-title>An association of polymyalgia rheumatica with myelodysplastic syndromes</article-title>. <source><italic>J Rheumatol</italic></source>. <year>1994</year>;<volume>21</volume>:<fpage>1357</fpage>&#x2013;<lpage>1359</lpage>.<pub-id pub-id-type="pmid">7966085</pub-id></mixed-citation>
      </ref>
      <ref id="R31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Garg</surname><given-names>ML</given-names></name><name><surname>Jain</surname><given-names>GV</given-names></name><name><surname>Maini</surname><given-names>PS</given-names></name></person-group>
<article-title>Sideroblastic anaemia presenting as monoarticular arthritis</article-title>. <source><italic>Acta Haematol</italic></source>. <year>1974</year>;<volume>52</volume>:<fpage>169</fpage>&#x2013;<lpage>172</lpage>.<pub-id pub-id-type="pmid">4214330</pub-id></mixed-citation>
      </ref>
      <ref id="R32">
        <label>32.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Kuzmich</surname><given-names>PV</given-names></name><name><surname>Ecker</surname><given-names>GA</given-names></name><name><surname>Karsh</surname><given-names>J</given-names></name></person-group>
<article-title>Rheumatic manifestations in patients with myelodysplastic and myeloproliferative diseases</article-title>. <source><italic>J Rheumatol</italic></source>. <year>1994</year>;<volume>21</volume>:<fpage>1649</fpage>&#x2013;<lpage>1654</lpage>.<pub-id pub-id-type="pmid">7799343</pub-id></mixed-citation>
      </ref>
      <ref id="R33">
        <label>33.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Lee</surname><given-names>BN</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Cohen</surname><given-names>EN</given-names></name><name><surname>Badoux</surname><given-names>X</given-names></name><name><surname>Wierda</surname><given-names>WG</given-names></name><name><surname>Estrov</surname><given-names>Z</given-names></name><name><surname>Faderl</surname><given-names>SH</given-names></name><name><surname>Keating</surname><given-names>MJ</given-names></name><name><surname>Ferrajoli</surname><given-names>A</given-names></name><name><surname>Reuben</surname><given-names>JM</given-names></name></person-group>
<article-title>Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia</article-title>. <source><italic>Cancer</italic></source>. <year>2011</year>;<volume>117</volume>:<fpage>3999</fpage>&#x2013;<lpage>4008</lpage>.<pub-id pub-id-type="pmid">21858802</pub-id></mixed-citation>
      </ref>
      <ref id="R34">
        <label>34.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Manganelli</surname><given-names>P</given-names></name><name><surname>Delsante</surname><given-names>G</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name><name><surname>Fietta</surname><given-names>P</given-names></name><name><surname>Quaini</surname><given-names>F</given-names></name></person-group>
<article-title>Remitting seronegative symmetrical synovitis with pitting oedema in a patient with myelodysplastic syndrome and relapsing polychondritis</article-title>. <source><italic>Clin Rheumatol</italic></source>. <year>2001</year>;<volume>20</volume>:<fpage>132</fpage>&#x2013;<lpage>135</lpage>.<pub-id pub-id-type="pmid">11346226</pub-id></mixed-citation>
      </ref>
      <ref id="R35">
        <label>35.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Mimura</surname><given-names>J</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Yabe</surname><given-names>H</given-names></name><name><surname>Nagai</surname><given-names>K</given-names></name><name><surname>Nakayama</surname><given-names>S</given-names></name></person-group>
<article-title>[Arthritis in a case of myelodysplastic syndromes]</article-title>. <source><italic>Rinsho Ketsueki</italic></source>. <year>1988</year>;<volume>29</volume>:<fpage>2292</fpage>&#x2013;<lpage>2296</lpage>.<pub-id pub-id-type="pmid">3246713</pub-id></mixed-citation>
      </ref>
      <ref id="R36">
        <label>36.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name><name><surname>Kumana</surname><given-names>CR</given-names></name></person-group>
<article-title>Polymyalgia rheumatica as the rheumatological manifestation of myelodysplastic syndrome in a Chinese patient</article-title>. <source><italic>Br J Rheumatol</italic></source>. <year>1996</year>;<volume>35</volume>:<fpage>496</fpage>&#x2013;<lpage>497</lpage>.<pub-id pub-id-type="pmid">8646448</pub-id></mixed-citation>
      </ref>
      <ref id="R37">
        <label>37.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Mufti</surname><given-names>GJ</given-names></name><name><surname>Figes</surname><given-names>A</given-names></name><name><surname>Hamblin</surname><given-names>TJ</given-names></name><name><surname>Oscier</surname><given-names>DG</given-names></name><name><surname>Copplestone</surname><given-names>JA</given-names></name></person-group>
<article-title>Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies</article-title>. <source><italic>Br J Haematol</italic></source>. <year>1986</year>;<volume>63</volume>:<fpage>143</fpage>&#x2013;<lpage>147</lpage>.<pub-id pub-id-type="pmid">3707859</pub-id></mixed-citation>
      </ref>
      <ref id="R38">
        <label>38.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Nam</surname><given-names>EJ</given-names></name><name><surname>Kang</surname><given-names>YM</given-names></name><name><surname>Kang</surname><given-names>HR</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Rho</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>MK</given-names></name><name><surname>Hyun</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>GW</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>NS</given-names></name></person-group>
<article-title>Rheumatoid arthritis associated with myelodysplastic syndrome: a case report</article-title>. <source><italic>J Korean Med Sci</italic></source>. <year>1999</year>;<volume>14</volume>:<fpage>319</fpage>&#x2013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">10402176</pub-id></mixed-citation>
      </ref>
      <ref id="R39">
        <label>39.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Nozaki</surname><given-names>Y</given-names></name><name><surname>Nagare</surname><given-names>Y</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Urase</surname><given-names>F</given-names></name><name><surname>Funauchi</surname><given-names>M</given-names></name></person-group>
<article-title>Successful treatment using tacrolimus plus corticosteroids in a patient with RA associated with MDS</article-title>. <source><italic>Rheumatol Int</italic></source>. <year>2008</year>;<volume>28</volume>:<fpage>487</fpage>&#x2013;<lpage>490</lpage>.<pub-id pub-id-type="pmid">17764011</pub-id></mixed-citation>
      </ref>
      <ref id="R40">
        <label>40.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Olive</surname><given-names>A</given-names></name><name><surname>del Blanco</surname><given-names>J</given-names></name><name><surname>Pons</surname><given-names>M</given-names></name><name><surname>Vaquero</surname><given-names>M</given-names></name><name><surname>Tena</surname><given-names>X</given-names></name></person-group>
<article-title>The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalan Group for the Study of RS3PE</article-title>. <source><italic>J Rheumatol</italic></source>. <year>1997</year>;<volume>24</volume>:<fpage>333</fpage>&#x2013;<lpage>336</lpage>.<pub-id pub-id-type="pmid">9034993</pub-id></mixed-citation>
      </ref>
      <ref id="R41">
        <label>41.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Paira</surname><given-names>S</given-names></name><name><surname>Graf</surname><given-names>C</given-names></name><name><surname>Roverano</surname><given-names>S</given-names></name><name><surname>Rossini</surname><given-names>J</given-names></name></person-group>
<article-title>Remitting seronegative symmetrical synovitis with pitting oedema: a study of 12 cases</article-title>. <source><italic>Clin Rheumatol</italic></source>. <year>2002</year>;<volume>21</volume>:<fpage>146</fpage>&#x2013;<lpage>149</lpage>.<pub-id pub-id-type="pmid">12086166</pub-id></mixed-citation>
      </ref>
      <ref id="R42">
        <label>42.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Pajus</surname><given-names>I</given-names></name><name><surname>Amor</surname><given-names>B</given-names></name></person-group>
<article-title>[Rheumatological manifestations associated with myelodysplastic and myeloproliferative syndromes]</article-title>. <source><italic>Rev Rhum Mal Osteoartic</italic></source>. <year>1992</year>;<volume>59</volume>:<fpage>11</fpage>&#x2013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">1579839</pub-id></mixed-citation>
      </ref>
      <ref id="R43">
        <label>43.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Pando</surname><given-names>JA</given-names></name><name><surname>McLean</surname><given-names>RM</given-names></name><name><surname>Flynn</surname><given-names>SD</given-names></name><name><surname>Duffy</surname><given-names>TJ</given-names></name></person-group>
<article-title>Leukemic synovitis as the cause of arthritis in myelodysplastic syndrome</article-title>. <source><italic>J Clin Rheumatol</italic></source>. <year>1995</year>;<volume>1</volume>:<fpage>125</fpage>&#x2013;<lpage>127</lpage>.<pub-id pub-id-type="pmid">19077960</pub-id></mixed-citation>
      </ref>
      <ref id="R44">
        <label>44.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Pilorge</surname><given-names>S</given-names></name><name><surname>Doleris</surname><given-names>LM</given-names></name><name><surname>Dreyfus</surname><given-names>F</given-names></name><name><surname>Park</surname><given-names>S</given-names></name></person-group>
<article-title>The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases</article-title>. <source><italic>Br J Haematol</italic></source>. <year>2011</year>;<volume>153</volume>:<fpage>664</fpage>&#x2013;<lpage>665</lpage>.<pub-id pub-id-type="pmid">21275970</pub-id></mixed-citation>
      </ref>
      <ref id="R45">
        <label>45.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Pipitone</surname><given-names>N</given-names></name><name><surname>Masini</surname><given-names>L</given-names></name><name><surname>Salvarini</surname><given-names>C</given-names></name></person-group>
<article-title>A case of arthritis and vasculitis associated with the refractory anemia with excess of blasts syndrome resistant to glucocorticoids treatment that responded favorably to TNF-alpha blockade</article-title>. <source><italic>Clin Experimental Rheum</italic></source>. <year>2006</year>;<volume>24</volume>:<fpage>S31</fpage>&#x2013;<lpage>S34</lpage>.</mixed-citation>
      </ref>
      <ref id="R46">
        <label>46.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Soubrier</surname><given-names>M</given-names></name><name><surname>Dubost</surname><given-names>JJ</given-names></name><name><surname>Fournier</surname><given-names>P</given-names></name><name><surname>Guillemot</surname><given-names>C</given-names></name><name><surname>Ristori</surname><given-names>JM</given-names></name></person-group>
<article-title>Myelodysplasia revealed by seropositive polyarthritis complicated by bicytopenia after the first methotrexate dose</article-title>. <source><italic>Joint Bone Spine</italic></source>. <year>2002</year>;<volume>69</volume>:<fpage>239</fpage>&#x2013;<lpage>240</lpage>.<pub-id pub-id-type="pmid">12027323</pub-id></mixed-citation>
      </ref>
      <ref id="R47">
        <label>47.</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Vardiman</surname><given-names>JW</given-names></name><name><surname>Thiele</surname><given-names>J</given-names></name><name><surname>Arber</surname><given-names>DA</given-names></name><name><surname>Brunning</surname><given-names>RD</given-names></name><name><surname>Borowitz</surname><given-names>MJ</given-names></name><name><surname>Porwit</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>NL</given-names></name><name><surname>Le Beau</surname><given-names>MM</given-names></name><name><surname>Hellstrom-Lindberg</surname><given-names>E</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name></person-group>
<article-title>The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes</article-title>. <source><italic>Blood</italic></source>. <year>2009</year>;<volume>114</volume>:<fpage>937</fpage>&#x2013;<lpage>951</lpage>.<pub-id pub-id-type="pmid">19357394</pub-id></mixed-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ACPA</term>
          <def>
            <p>anti-citrullinated protein antibody</p>
          </def>
        </def-item>
        <def-item>
          <term>ACR</term>
          <def>
            <p>American College of Rheumatology</p>
          </def>
        </def-item>
        <def-item>
          <term>AML</term>
          <def>
            <p>acute myeloid leukemia</p>
          </def>
        </def-item>
        <def-item>
          <term>ANA</term>
          <def>
            <p>antinuclear antibodies</p>
          </def>
        </def-item>
        <def-item>
          <term>CMML</term>
          <def>
            <p>chronic myelomonocytic leukemia</p>
          </def>
        </def-item>
        <def-item>
          <term>CRP</term>
          <def>
            <p>C-reactive protein</p>
          </def>
        </def-item>
        <def-item>
          <term>DAS28-CRP</term>
          <def>
            <p>disease activity score 28 based on C-reactive protein</p>
          </def>
        </def-item>
        <def-item>
          <term>ESR</term>
          <def>
            <p>erythrocyte sedimentation rate</p>
          </def>
        </def-item>
        <def-item>
          <term>IPSS</term>
          <def>
            <p>International Prognostic Scoring System</p>
          </def>
        </def-item>
        <def-item>
          <term>MDS</term>
          <def>
            <p>myelodysplastic syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>MDS-U</term>
          <def>
            <p>unclassified MDS</p>
          </def>
        </def-item>
        <def-item>
          <term>RAEB1</term>
          <def>
            <p>refractory anemia with excess blasts-1</p>
          </def>
        </def-item>
        <def-item>
          <term>RAEB2</term>
          <def>
            <p>refractory anemia with excess blasts-2</p>
          </def>
        </def-item>
        <def-item>
          <term>RARS</term>
          <def>
            <p>refractory anemia with ring sideroblasts</p>
          </def>
        </def-item>
        <def-item>
          <term>RCMD</term>
          <def>
            <p>refractory cytopenia with multilineage dysplasia</p>
          </def>
        </def-item>
        <def-item>
          <term>RCUD</term>
          <def>
            <p>refractory cytopenia with unilineage dysplasia</p>
          </def>
        </def-item>
        <def-item>
          <term>RS3PE</term>
          <def>
            <p>remitting seronegative symmetrical synovitis with pitting edema</p>
          </def>
        </def-item>
        <def-item>
          <term>WHO</term>
          <def>
            <p>World Health Organization</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
  </back>
</article>
</pmc-articleset>
